Evidence map›Paper›PMID 41557795›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Sleep loss induces cholesterol-associated myelin dysfunction.

Reyila Simayi, Eleonora Ficiarà, Oluwatomisin Faniyan, Antonio Cerdán Cerdá, Amina Aboufares El Alaoui, Rosamaria Fiorini, Adele Cutignano, Fabiana Piscitelli, Aroa S Maroto, Alexandra Santos and 4 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Reyila Simayi *School of Pharmacy, University of Camerino, Camerino 62032, Italy.ORCID 0000-0002-2029-0047
Eleonora Ficiarà *School of Pharmacy, University of Camerino, Camerino 62032, Italy.
Oluwatomisin FaniyanCenter for Neuroscience, University of Camerino, Camerino 62032, Italy.
Antonio Cerdán CerdáInstituto de Neurociencias (Consejo Superior de Investigaciones Científicas - Universidad Miguel Hernández), San Juan de Alicante 03550, Spain.ORCID 0000-0001-6641-014X
Amina Aboufares El AlaouiCenter for Neuroscience, University of Camerino, Camerino 62032, Italy.
Rosamaria FioriniDepartment of Life and Environmental Sciences, Marche Polytechnic University, Ancona 60100, Italy.ORCID 0000-0003-1675-6200
Adele CutignanoIstituto di Chimica Biomolecolare-Consiglio Nazionale delle Ricerche, Pozzuoli 80078, Italy.ORCID 0000-0003-3035-9252
Fabiana PiscitelliIstituto di Chimica Biomolecolare-Consiglio Nazionale delle Ricerche, Pozzuoli 80078, Italy.
Aroa S MarotoInstituto de Neurociencias (Consejo Superior de Investigaciones Científicas - Universidad Miguel Hernández), San Juan de Alicante 03550, Spain.ORCID 0000-0002-4971-2127
Alexandra SantosInstituto de Neurociencias (Consejo Superior de Investigaciones Científicas - Universidad Miguel Hernández), San Juan de Alicante 03550, Spain.
Federico Del GalloSchool of Pharmacy, University of Camerino, Camerino 62032, Italy.
Luisa de VivoSchool of Pharmacy, University of Camerino, Camerino 62032, Italy.ORCID 0000-0002-5676-9279
Silvia De SantisInstituto de Neurociencias (Consejo Superior de Investigaciones Científicas - Universidad Miguel Hernández), San Juan de Alicante 03550, Spain.ORCID 0000-0001-9739-6926
Michele BellesiCenter for Neuroscience, University of Camerino, Camerino 62032, Italy.ORCID 0000-0002-3922-0188

Funding

Cariverona Foundation PhD ScholarshipGeneralitat Valenciana through a Subvencion para la contratación de investigadoras e investigadores doctores de excelencia 2021 CIDEGENT/2021/015Giovanni Armenise-Harvard Foundation (GAHF) CDAPRIN 2022 2022YSTP5Lthe European Union - Next generation EU, Ministry of University and Research-Promotion and Development Fund- Ministerial Decree N737/2021 MYSLEEPthe Programs for Centres of Excellence in R&D Severo Ochoa CEX2021-001165-Sthe Spanish Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación PID2021-128909NA-I00Wellcome TrustWellcome Trust (WT) 215267/Z/19/ZWellcome Trust (WT) 217546/Z/19/Z
6 · The paper itself

Abstract

The increasing prevalence of sleep deprivation poses a public health challenge in modern society. Manifestations of reduced alertness, such as slowed reaction times and increased errors, are well-documented behavioral indicators of sleep loss (SL). Yet, the biological consequences of sleep deprivation and their role in behavioral impairment remain elusive. Our study reveals significant effects of sleep deprivation on myelin integrity. As a result, we identify increased conduction delays in nerve signal propagation, hindered interhemispheric synchronization, and impaired cognitive and motor performance associated with SL. By profiling oligodendrocyte transcriptome and lipidome, we observe SL-induced endoplasmic reticulum stress and lipid metabolism dysregulation, particularly affecting cholesterol homeostasis. Boosting cholesterol transport to myelin sheaths prevents SL effects on nerve signal propagation and behavior. Our findings highlight a possible role of oligodendrocyte cholesterol dysregulation in behavioral deficits associated with SL and unveil a novel target for intervention.

Indexed as

CholesterolMyelin SheathSleep DeprivationAnimalsEndoplasmic Reticulum StressLipid MetabolismMiceOligodendrogliaCholesterolmyelinoligodendrocytesleepwhite matter

Identifiers

PMID41557795
PMCPMC12846829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.